Urban C, Benesch M, Sykora K W, Schwinger W, Lackner H
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescence Medicine, Medical University of Graz, Graz, Austria.
Bone Marrow Transplant. 2005 Mar;35(6):591-4. doi: 10.1038/sj.bmt.1704792.
Conditioning including total body/lymphoid irradiation is widely used to prevent graft rejection in patients with refractory severe aplastic anemia (SAA) undergoing hemopoietic cell transplantation (HCT) from alternative donors and or after graft manipulation. To reduce regimen-related toxicity we transplanted three children with refractory SAA after conditioning with radiotherapy-free regimens. Conditioning included fludarabine 175-180 mg/m2 in all patients. In addition, patient 1 (failing two previous grafts) received thiotepa 10 mg/kg and Campath-1H 60 mg/m2; patient 2 cyclophosphamide 120 mg/kg, thiotepa 15 mg/kg and OKT-3 0.1 mg/kg/day for 4 weeks; and patient 3 cyclophosphamide 120 and ATG 90 mg/kg. Stem cell source was unmanipulated marrow from the same unrelated donor as for the two previous transplantations in patient 1 and CD34+-purified peripheral blood stem cells from an HLA-matched unrelated donor and from the haploidentical mother in patients 2 and 3. Only patient 1 received graft-versus-host disease (GVHD) prophylaxis with cyclosporine A and mycophenolate mofetil. Follow-up is now 30, 51, and 15 months. None of the patients developed GVHD. All patients have normal counts with complete donor chimerism. Fludarabine-based conditioning is powerfully immunosuppressive and may be used for children with refractory SAA undergoing HCT from alternative donors even after rejection following previous HCT.
预处理包括全身/淋巴照射,广泛用于预防难治性严重再生障碍性贫血(SAA)患者在接受来自替代供体的造血细胞移植(HCT)时或在移植物操作后发生移植物排斥反应。为了降低与方案相关的毒性,我们对3例难治性SAA患儿采用无放疗方案进行预处理后进行了移植。所有患者的预处理均包括氟达拉滨175 - 180 mg/m²。此外,患者1(之前两次移植失败)接受了塞替派10 mg/kg和Campath-1H 60 mg/m²;患者2接受了环磷酰胺120 mg/kg、塞替派15 mg/kg和OKT-3 0.1 mg/kg/天,共4周;患者3接受了环磷酰胺120 mg/kg和抗胸腺细胞球蛋白(ATG)90 mg/kg。干细胞来源方面,患者1与前两次移植相同的无关供体的未处理骨髓,患者2和3分别来自HLA匹配的无关供体和单倍体相合母亲的CD34⁺纯化外周血干细胞。只有患者1接受了环孢素A和霉酚酸酯预防移植物抗宿主病(GVHD)。目前随访时间分别为30、51和15个月。所有患者均未发生GVHD。所有患者血细胞计数正常,供体完全嵌合。基于氟达拉滨的预处理具有强大的免疫抑制作用,可用于难治性SAA患儿接受来自替代供体的HCT,即使在先前HCT后发生排斥反应之后。